Sugi Predict

Sugi Predict / Compounds / SCHEMBL1633704

SCHEMBL1633704

SCHEMBL1633704

Brc1cccc(C2OCCO2)n1

nearest known ligand 0.33

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 1/20 0.31
▸ CASP6 P55212 1/20 0.31
▸ KDM1A O60341 1/20 0.30
▸ MAOA P21397 1/20 0.30
▸ MAOB P27338 1/20 0.30
▸ GRIN2D O15399 1/20 0.30
▸ GRIN3B O60391 1/20 0.30
▸ GRIN1 Q05586 1/20 0.30
▸ GRIN2A Q12879 1/20 0.30
▸ GRIN2B Q13224 1/20 0.30
▸ GRIN2C Q14957 1/20 0.30
▸ GRIN3A Q8TCU5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30303121 1.00 NSD2 (0.31) NSD2CASP6KDM1AMAOAMAOB
SCHEMBL5313806 0.92 PARP1 (0.30) —
SCHEMBL7026337 0.78 NSD2 (0.32) NSD2CASP6
SCHEMBL29318590 0.78 TSHR (0.37) KDM1AMAOAMAOBGRIN2DGRIN3B
SCHEMBL6854102 0.76 DRD4 (0.38) NSD2CASP6
SCHEMBL28340476 0.76 TSHR (0.41) NSD2CASP6
SCHEMBL4346655 0.76 CHRNA7 (0.38) —
SCHEMBL1854614 0.76 CCR1 (0.46) NSD2CASP6
SCHEMBL27823308 0.76 DDB1 (0.46) NSD2CASP6KDM1AMAOAMAOB
SCHEMBL6984191 0.76 CHRNA7 (0.43) NSD2CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545683-B2 CBP/catenin signaling pathway inhibitors and uses thereof 3+2 PHARMA, LLC (US) 2026-02-10 — — US disclosed
US-20250188106-A1 SUBSTITUTED IMIDAZO[1,5-A]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-06-12 — — US disclosed
US-20230348476-A1 CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF 3 2 PHARMA LLC (US) 2023-11-02 — — US disclosed
US-20230348476-A1 CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF 3 2 PHARMA LLC (US) 2023-11-02 — — US disclosed
US-20230348476-A1 CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF 3 2 PHARMA LLC (US) 2023-11-02 — — US disclosed
WO-2023172667-A2 SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-09-14 — — WO disclosed
WO-2023172667-A2 SUBSTITUTED IMIDAZO[1,5-a]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-09-14 — — WO disclosed
CN-116472267-A Butyrylcholinesterase reactivating agent 法兰西国由中央军队卫生服务局代表 2023-07-21 — — CN disclosed
US-11655253-B2 CBP/catenin signaling pathway inhibitors and uses thereof 3+2 PHARMA, LLC (US) 2023-05-23 — — US disclosed
US-11655253-B2 CBP/catenin signaling pathway inhibitors and uses thereof 3+2 PHARMA, LLC (US) 2023-05-23 — — US disclosed
EP-1601676-A2 FUSED IMIDAZOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS Pfizer Products Inc. (US) 2005-12-07 — — EP disclosed
EP-1499308-A2 TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME BIOGEN, INC. (US) 2005-01-26 — — EP disclosed
WO-2004078110-A2 FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS PFIZER PRODUCTS INC. (US) 2004-09-16 — — WO disclosed
US-20040176390-A1 Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors PFIZER INC 2004-09-09 — — US disclosed
WO-2003087304-A2 TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME BIOGEN, INC. (US) 2003-10-23 — — WO disclosed
EP-0085959-B1 AROMATIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1989-04-19 — — EP disclosed
EP-0249950-A1 Aromatic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1987-12-23 — — EP disclosed
US-4650807-A Antihistaminic compositions and methods containing pyridine derivatives BURROUGHS WELLCOME CO. (US) 1987-03-17 — — US disclosed
US-4501893-A ANTIHISTAMINE/CANT CONTAINS CARBOXYL GROUPS MEDEVA CALIFORNIA, INC. 1985-02-26 — — US disclosed
EP-0085959-A2 Aromatic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1983-08-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348476-A1 CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF CREBBP, CREB1, EP300 NSD2 2914/4885CASP6 3221/4885KDM1A 1493/4885
US-12545683-B2 CBP/catenin signaling pathway inhibitors and uses thereof CREBBP, CREB1, CTNNB1 NSD2 2059/4885CASP6 2441/4885KDM1A 1375/4885
US-11655253-B2 CBP/catenin signaling pathway inhibitors and uses thereof CREBBP, CREB1, EP300 NSD2 2914/4885CASP6 3221/4885KDM1A 1493/4885
US-20250188106-A1 SUBSTITUTED IMIDAZO[1,5-A]PYRIDINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME NDC1, NUDC, PAICS NSD2 803/4885CASP6 4060/4885KDM1A 1255/4885
US-20040176390-A1 Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors SMAD3, TGFBR1, SMAD2 NSD2 3656/4885CASP6 2478/4885KDM1A 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.